Chronos Archive seal

Review checklist: Joe Frazier (HR-BX004)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the FIB-4 to elastography pathway, the diagnosis of compensated cirrhosis from a liver stiffness of 17.6 kPa with platelets of 138 and ultrasound findings, the endoscopy rather than a beta-blocker, six-monthly ultrasound with AFP, semaglutide with metformin, the eGFR without a race term, amlodipine with lisinopril, aspirin not used, and the cognitive screen without a CTE diagnosis.
provenance reviewnot_startedSources: an ESPN Classic biography and an ESPN Classic article written during his life, and obituaries from ESPN, the Associated Press (The Philadelphia Inquirer, CBS Los Angeles, The Vindicator) and The Irish Times. A posthumous magazine profile was not used.
safe messaging reviewnot_startedRecent-death rule: only what was reported publicly during his life or in obituaries and statements by his manager and family. No sick visit. No mental health or substance claim is made. The liver disease, cognitive screen and every clinical finding are synthetic. No living relative is named, and his rival is not named.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. Frazier died in 2011, so the rule applies. The case uses only what was reported publicly during his life (two ESPN Classic pieces) and in obituaries and the public statements of his manager, a family friend and his family (ESPN, the Associated Press as carried by The Philadelphia Inquirer, CBS Los Angeles and The Vindicator, and The Irish Times). No sick visit is added. No claim concerns mental health or substance use; the modern PHQ screens are synthetic and below the threshold for a safety assessment. His death is recorded once (CLM-0010) in one plain sentence; the liver cancer is recorded once (CLM-0009) as history and does not appear in the modern episode.
  2. Diabetes and hypertension. Both were reported publicly during his life (ESPN Classic, CLM-0008), so the modern diabetes and hypertension are linked to a documented claim. Their duration (about twelve years), severity, treatment and every value are synthetic.
  3. Liver disease is synthetic. No source read reports fatty liver disease, fibrosis or cirrhosis in his life, or any cause for the liver cancer. The modern MASLD with compensated cirrhosis is a synthetic choice made to teach FIB-4, elastography and six-monthly surveillance that can find liver cancer early. The case does not suggest that this was the cause of his cancer, and his alcohol use was not researched and is not used.
  4. The left eye. The cataract found in 1964, his visual impairment when he turned professional and the 1975 vision figures were reported during his life (CLM-0004). Accounts that he hid the eye from examiners by memorizing the chart or switching hands appear in a magazine profile published after his death and in fan and forum sites; they are outside the rule and are not used. Accounts of a training injury and later surgery come from similar sources and are not used. The modern left-eye acuity is synthetic.
  5. Brain health. The roster lists occupational traumatic brain injury; no source read reports a brain injury or cognitive problem in his life. The modern episode records only the documented career (CLM-0005, CLM-0006), his synthetic question about memory, and a synthetic normal MoCA. No chronic traumatic encephalopathy or traumatic encephalopathy syndrome diagnosis is made.
  6. Roster leads not used. The rivalry's “bitterness” and its psychological burden are not recorded, because they would be mental health claims beyond the public medical record. Financial trouble is recorded only as reported in the AP obituary (CLM-0007).
  7. Real people. His rival, who has a record in this dataset, is not named, nor are other opponents. His trainer and manager appear only as sources of the public statements, unnamed in claims. No relative is named and nothing is attributed to any relative; the family's release is cited only for the fact of his death.
  8. Alias. “Smokin' Joe,” his nickname and the title of his 1996 autobiography (CLM-0011), appears in no other record. The apostrophe is a plain ASCII apostrophe; the build and the cross-case check handle it.
  9. Index age and dates. The index visit on February 16, 2026 maps to February 16, 2008, when he was 64, three and a half years before the liver cancer diagnosis in October 2011. The synthetic date of birth is January 12, 1962 (shift 18 years). The chronic-care visits on March 2, April 13, May 18 and September 14, 2026, the endoscopy on April 6, the eye examination on June 22 and the preventive visit on July 13, 2026 map to the same days of 2008. He lived and ran his gym in Philadelphia in those years; the episode does not contradict it. Past medical history includes only events up to the early 2000s.
  10. Synthetic clinical picture. Every value is synthetic: the A1c, kidney tests, urine albumin, lipids, liver tests, FIB-4 (3.43 and 3.12), liver stiffness (17.6 kPa), controlled attenuation parameter, AFP, INR, MoCA, PHQ scores, the ECG, foot, eye, ultrasound and endoscopy findings, the PSA (narrative only), the medicines and the outcomes. Height (182 cm) and weights are synthetic. Hepatitis, HIV, iron and autoimmune test results are narrative.
  11. Clinical judgment calls. (1) Compensated cirrhosis was diagnosed from a FIB-4 above 2.67, a stiffness of 17.6 kPa, platelets of 138 and ultrasound findings, without biopsy. (2) Endoscopy rather than a beta-blocker, because a stiffness of 15 to 25 kPa with platelets below 150 cannot rule portal hypertension in or out under Baveno VII; no varices were found. (3) Semaglutide was chosen for cardiovascular and kidney benefit, weight and steatotic liver disease; metformin and atorvastatin continued. (4) Amlodipine was added to lisinopril. (5) Aspirin was not used for primary prevention because of bleeding risk with cirrhosis. (6) RSV vaccine at 64 because of diabetes and chronic liver disease. (7) The preventive visit is a periodic adult preventive visit (CPT 99396 with 99497 in plain text), since he is under 65.
  12. Preventive visit. Colonoscopy ordered (last more than ten years earlier); PSA after shared decision-making, with his higher risk as a Black man discussed; MoCA 26; no lung or aortic screening (never smoked); zoster vaccine dose 1; advance care planning records an unnamed agent.
  13. Focused visits. The four chronic-care follow-ups (two weeks with the consultation, eight weeks, three months and seven months) are documented as focused visits on the CMID diabetes, hypertension and hyperlipidemia monographs with the ADA Standards of Care 2026 and the 2025 AHA/ACC guideline, and on the AASLD 2023 MASLD and HCC guidance and Baveno VII. One deviation is recorded instead of an invented result: the dilated eye examination planned at intake had not been done by three months because he missed the appointment and it was not rebooked; it mattered because A1c was falling quickly on semaglutide; no harm is known (no new symptoms, and the examination in June found no retinopathy); the clinic rebooked it on a day he chose with a reminder call. Synthetic findings introduced: no varices on endoscopy and a clear six-month surveillance ultrasound.
  14. Consultation. The hepatology referral and the consultation by Anjali Deshpande, MD (a fictional consultant), on the day of the two-week visit, are S. The consultant answers the five referral questions in line with what the record shows afterwards: MASLD with compensated cirrhosis, Child-Pugh A; ultrasound with AFP every six months, done in March and September; endoscopy within six weeks (no varices, repeat in two years); semaglutide with metformin and atorvastatin continued; hepatitis A and B, PCV20 and seasonal vaccines; no alcohol, no NSAIDs, acetaminophen limited; and repeat elastography at one year.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-05-18
Progress note 04 (C-CDA)
Dilated eye examinationAt the start of care, then every 1 to 2 years; promptly when A1c is falling quickly on a GLP-1 receptor agonistPlanned at intake but not done three months later: he missed the appointment, and it was not rebooked. No harm is known: he has no new eye symptoms, and the later examination found no retinopathy. Corrective action: the clinic rebooked it on a day he chose, with a reminder call, before the A1c falls further

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-03-02
Progress note 02 (C-CDA)
ReferralVariceal screeningOrderedUpper endoscopy booked for next month
2026-04-13
Progress note 03 (C-CDA)
ExaminationDilated eye examinationOrderedEye clinic appointment next month
2026-07-13
Progress note 05 (C-CDA)
PreventionColorectal cancer screeningOrderedLast colonoscopy more than ten years ago and normal; colonoscopy ordered, with anesthesia aware of his cirrhosis
2026-07-13
Progress note 05 (C-CDA)
PreventionProstate cancer screeningOrderedShared decision for men 55 to 69, discussing his higher risk as a Black man; he chose a PSA test, drawn today

Evidence to check

Retrospective claims (R)

None.

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-02-16Hemoglobin A1c8.4% (high)High
2026-02-16Glucose (fasting)168 mg/dL (high)High
2026-02-16Total cholesterol212 mg/dL (high)High
2026-02-16LDL cholesterol132 mg/dL (high)High
2026-02-16HDL cholesterol38 mg/dL (low)Low
2026-02-16Triglycerides210 mg/dL (high)High
2026-02-16AST48 U/L (high)High
2026-02-16Platelets138 10*3/uL (low)Low
2026-03-02Liver stiffness (transient elastography)17.6 kPa (high)High
2026-04-13Triglycerides168 mg/dL (high)High
2026-04-13AST44 U/L (high)High
2026-05-18Hemoglobin A1c7.3% (high)High
2026-09-14Hemoglobin A1c6.8% (high)High
2026-09-14Platelets140 10*3/uL (low)Low